SEATTLE — There's new hope for people in the early stages of Alzheimer's disease. A new medication called donanemab appears ...

The second U.S. drug shown to slow the progression of early Alzheimer's has arrived in Seattle-area clinics. One of the first ...

A new study found that a gene recently recognized as a biomarker for Alzheimer's disease is actually a cause of it, due to its previously unknown secondary function that triggers a pathway that ...

UW has begun treating patients with donanemab, a new Alzheimer’s medication that may slow cognitive decline in people with ...

A directive in January from the National Institutes of Health aimed to reduce funding for many of the essential costs that ...

Eli Lilly has requested Europe's drug regulator to re-examine its opinion on the company's Alzheimer's drug, the agency said ...

The former Virginia Tech signal caller transferred to UCF, bringing him closer home to his family.